Orelabrutinib Tablets

Obtunib tablets are indicated for the following treatments:
Adult mantle cell lymphoma (MCL) patients who have received at least one previous treatment.
Adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who have received at least one previous treatment.
This product is a selective Bruton’s tyrosine kinase (BTK) inhibitor that can inhibit the activation of BTK-related signaling pathways and inhibit the overactivation and proliferation of B cells.